The Australian Government is continuing to deliver cheaper medicines with Australians living with cerebral palsy to pay less for an expanded medicine listing on the Pharmaceutical Benefits Scheme (PBS).
IncobotulinumtoxinA (Xeomin®) will be expanded for the treatment of moderate to severe spasticity of the upper limb and dynamic equinus foot deformity in patients with cerebral palsy.
Cerebral palsy is a neurological disorder affecting a person's body movements. Spasticity is a common symptom affecting approximately 70-90 per cent of children with cerebral palsy.
Xeomin® works by helping muscles to relax by blocking the chemical signals that cause the stiffening of muscles and spasticity.
In 2025, around 2,300 patients accessed a comparable treatment through the PBS. Without PBS subsidy patients might pay over $1,400 per script.
The PBS listing means eligible patients will pay a maximum of $25 per script, or just $7.70 with a concession card.
Since July 2022, the Australian Government has approved extra funding for 431 new and amended listings on the PBS.
Quotes attributable to Minister Butler:
"The listing of Xeomin will be life changing for thousands of Australians impacted by cerebral palsy, a lifelong neurological disorder.
"For many patients this medicine can improve day-to-day life and provide greater independence.
"The expanded PBS listing is part of the Albanese Government's commitment to make medicines cheaper and more accessible for all Australians."
